<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>FDA Drug Approvals</title>
<link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600&amp;family=Lato:wght@400;700&amp;display=swap" rel="stylesheet"/>
<link href="https://cdn.datatables.net/2.0.7/css/dataTables.dataTables.min.css" rel="stylesheet"/>
<link href="https://cdn.datatables.net/buttons/3.0.2/css/buttons.dataTables.min.css" rel="stylesheet"/>
<style>
    :root{
      --light-blue:#26bcf8;
      --border:#d9dee5;
      --bg:#f5f7fb;
      --text:#1b2b41;
    }
    body { font-family:'Lato', Arial, sans-serif; margin:0; background:var(--bg); color:var(--text); font-size: 14px; }
    header { background:#0f2230; color:#fff; }
    .container { max-width: 100%; margin:0 auto; padding: 1rem 1.25rem; }
    h1 { font-family:'Open Sans', Arial, sans-serif; font-weight:600; font-size:1rem; margin:.25rem 0; }
    .table-responsive { width: 100%; overflow-x: auto; background:#fff; border:1px solid #e3e8ef; border-radius:10px; box-shadow:0 6px 18px rgba(0,0,0,.06); padding:.4rem; }
    table { width: 100% !important; border-collapse: collapse; }
    .table-bordered { border:1px solid var(--border); }
    .table-bordered th, .table-bordered td { border:1px solid var(--border); }
    thead th { background: var(--light-blue); color:#fff; font-weight:600; font-size: 0.9rem; }
    thead th, tbody td { padding:.55rem .6rem; vertical-align: top; font-size: 0.85rem; }
    tbody td { white-space: normal; word-break: break-word; }
    .dataTables_wrapper .dt-buttons { margin:.5rem .25rem; }
    .dt-buttons .dt-button { border:1px solid #cbd5e1; border-radius:6px; background:#fff; color:#1f2937; font-size: 0.85rem; }
    .dt-buttons .dt-button:hover { background:#f3f7fb; }
    /* Make long links wrap nicely */
    td a { word-break: break-all; }
  </style>
</head>
<body>
<header>
<div class="container">
<h1>FDA Drug Approvals</h1>
</div>
</header>
<main class="container">
<div class="table-responsive">
<table class="dataframe display table table-bordered" id="tbl_main">
<thead>
<tr style="text-align: right;">
<th>Approval Date</th>
<th>Drug Name</th>
<th>Company</th>
<th>Application ID</th>
<th>Active Ingredients</th>
<th>FDA-approved use on approval date</th>
<th>Submission Classification</th>
<th>Review Priority</th>
<th>Drugs@FDA Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025-08-01</td>
<td>E-Z-Disk</td>
<td>Bracco</td>
<td>NDA #219840</td>
<td>Barium Sulfate</td>
<td></td>
<td></td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219840</td>
</tr>
<tr>
<td>2025-08-08</td>
<td>Hernexeos</td>
<td>Boehringer Ingelheim Pharmaceuticals Inc</td>
<td>NDA #219042</td>
<td>Zongertinib</td>
<td>To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy</td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219042</td>
</tr>
<tr>
<td>2025-08-08</td>
<td>Kyxata</td>
<td>Avyxa Holdings</td>
<td>NDA #219921</td>
<td>Carboplatin</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219921</td>
</tr>
<tr>
<td>2025-08-12</td>
<td>Brinsupri</td>
<td>Insmed Inc</td>
<td>NDA #217673</td>
<td>Brensocatib</td>
<td>To treat non-cystic fibrosis bronchiectasis</td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217673</td>
</tr>
<tr>
<td>2025-08-15</td>
<td>Cyklx</td>
<td>American Genomics LLC</td>
<td>NDA #218643</td>
<td>Articaine</td>
<td></td>
<td>Type 3 - New Dosage Form and Type 4 - New Combination</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218643</td>
</tr>
<tr>
<td>2025-08-15</td>
<td>Tonmya</td>
<td>Tonix Pharmaceuticals Inc</td>
<td>NDA #219428</td>
<td>Cyclobenzprine</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219428</td>
</tr>
<tr>
<td>2025-07-03</td>
<td>Ekterly</td>
<td>Kalvista</td>
<td>NDA #219301</td>
<td>Sebetralstat</td>
<td>To treat acute attacks of hereditary angioedema</td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219301</td>
</tr>
<tr>
<td>2025-07-15</td>
<td>Kirsty</td>
<td>Biocon Biologics Inc</td>
<td>BLA #761188</td>
<td>Insulin Aspart-XJHZ</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761188</td>
</tr>
<tr>
<td>2025-07-16</td>
<td>Famotidine</td>
<td>Sagent</td>
<td>NDA #219935</td>
<td>Famotidine</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219935</td>
</tr>
<tr>
<td>2025-07-23</td>
<td>Anzupgo</td>
<td>Leo Pharma AS</td>
<td>NDA #219155</td>
<td>Delgocitinib</td>
<td>To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response</td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219155</td>
</tr>
<tr>
<td>2025-07-23</td>
<td>Vostally</td>
<td>Rosemont Pharms</td>
<td>NDA #219757</td>
<td>Ramipril</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219757</td>
</tr>
<tr>
<td>2025-07-24</td>
<td>Sdamlo</td>
<td>Brillian Pharma</td>
<td>NDA #219531</td>
<td>Amlodipine Besylate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219531</td>
</tr>
<tr>
<td>2025-07-24</td>
<td>Doptelet Sprinkle</td>
<td>Akarx Inc</td>
<td>NDA #219696</td>
<td>Avatrombopag Maleate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219696</td>
</tr>
<tr>
<td>2025-07-28</td>
<td>Sephience</td>
<td>PTC Therap</td>
<td>NDA #219666</td>
<td>Sepiapterin</td>
<td>To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet</td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219666</td>
</tr>
<tr>
<td>2025-07-29</td>
<td>Vyscoxa</td>
<td>Codadose Inc</td>
<td>NDA #211759</td>
<td>Celecoxib</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211759</td>
</tr>
<tr>
<td>2025-07-30</td>
<td>Atmeksi</td>
<td>Rosemont Pharms</td>
<td>NDA #219843</td>
<td>Methocarbamol</td>
<td></td>
<td></td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219843</td>
</tr>
<tr>
<td>2025-07-31</td>
<td>VIZZ</td>
<td>LENZ Therap</td>
<td>NDA #218585</td>
<td>Aceclidine Hydrochloride</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218585</td>
</tr>
<tr>
<td>2025-07-31</td>
<td>Alhemo</td>
<td>Novo Nordisk Inc</td>
<td>BLA #761428</td>
<td>Concizumab</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761428</td>
</tr>
<tr>
<td>2025-06-05</td>
<td>Xifyrm</td>
<td>Azurity</td>
<td>NDA #218395</td>
<td>Meloxicam</td>
<td></td>
<td></td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218395</td>
</tr>
<tr>
<td>2025-06-05</td>
<td>Widaplik</td>
<td>George Medicines</td>
<td>NDA #219423</td>
<td>Amlodipine Besylate; Indapamide; Telmisartan</td>
<td></td>
<td>Type 4 - New Combination</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219423</td>
</tr>
<tr>
<td>2025-06-09</td>
<td>Rocuronium Bromide</td>
<td>Fresenius Kabi USA</td>
<td>NDA #217472</td>
<td>Rocuronium Bromide</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217472</td>
</tr>
<tr>
<td>2025-06-09</td>
<td>Enflonsia</td>
<td>Merck Sharp Dohme</td>
<td>BLA #761432</td>
<td>Clesrovimab-cfor</td>
<td>To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV seasonÂ Drug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761432</td>
</tr>
<tr>
<td>2025-06-10</td>
<td>Brukinsa</td>
<td>Beone Medicines USA</td>
<td>NDA #218785</td>
<td>Zanubrutinib</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218785</td>
</tr>
<tr>
<td>2025-06-11</td>
<td>Ibtrozi</td>
<td>Nuvation</td>
<td>NDA #219713</td>
<td>Taletrectinib Adipate</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219713</td>
</tr>
<tr>
<td>2025-06-12</td>
<td>Zusduri</td>
<td>Urogen Pharma</td>
<td>NDA #215793</td>
<td>Mitomycin</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=215793</td>
</tr>
<tr>
<td>2025-06-16</td>
<td>Arynta</td>
<td>Azurity</td>
<td>NDA #219847</td>
<td>Lisdexamfetamine Dimesylate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219847</td>
</tr>
<tr>
<td>2025-06-16</td>
<td>Carbon Dioxide, USP</td>
<td>General Distributing Company</td>
<td>NDA #220634</td>
<td>Carbon Dioxide</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220634</td>
</tr>
<tr>
<td>2025-06-16</td>
<td>Andembry</td>
<td>CSL Behring LLC</td>
<td>BLA #761367</td>
<td>Garadacimab-gxii</td>
<td>To prevent attacks of hereditary angioedema</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761367</td>
</tr>
<tr>
<td>2025-06-18</td>
<td>Yeztugo</td>
<td>Gilead Sciences Inc</td>
<td>NDA #220018</td>
<td>Lenacapavir</td>
<td></td>
<td>Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220018</td>
</tr>
<tr>
<td>2025-06-18</td>
<td>Yeztugo</td>
<td>Gilead Sciences Inc</td>
<td>NDA #220018</td>
<td>Lenacapavir Sodium</td>
<td></td>
<td>Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220018</td>
</tr>
<tr>
<td>2025-06-18</td>
<td>Yeztugo</td>
<td>Gilead Sciences Inc</td>
<td>NDA #220020</td>
<td>Lenacapavir Sodium</td>
<td></td>
<td>Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220020</td>
</tr>
<tr>
<td>2025-06-23</td>
<td>Datroway</td>
<td>Daiichi Sankyo Inc</td>
<td>BLA #761464</td>
<td>Datopotamab Deruxtecan-dlnk</td>
<td>To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic diseaseDrug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761464</td>
</tr>
<tr>
<td>2025-06-27</td>
<td>Avgemsi</td>
<td>Avyxa Holdings</td>
<td>NDA #219920</td>
<td>Gemcitabine Hydrochloride</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219920</td>
</tr>
<tr>
<td>2025-05-08</td>
<td>Avmapki Fakzynja Co-pack (copackaged)</td>
<td>Verastem Inc</td>
<td>NDA  #219616</td>
<td>Avutometinib Potassium; Defactinib Hydrochloride</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219616</td>
</tr>
<tr>
<td>2025-05-14</td>
<td>Brekiya (autoinjector)</td>
<td>Amneal</td>
<td>NDA #215400</td>
<td>Dihydroergotamine Mesylate</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=215400</td>
</tr>
<tr>
<td>2025-05-14</td>
<td>Emrelis</td>
<td>Abbvie Inc</td>
<td>BLA  #761384</td>
<td>Telisotuzumab Vedotin-tllv</td>
<td>To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapyÂ Drug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761384</td>
</tr>
<tr>
<td>2025-05-20</td>
<td>Aususvar</td>
<td>Auson Pharm</td>
<td>NDA  #217062</td>
<td>Rivaroxaban</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217062</td>
</tr>
<tr>
<td>2025-05-22</td>
<td>Starjemza</td>
<td>Bio-thera Solutions LTD</td>
<td>BLA  #761419</td>
<td>Ustekinumab-hmny</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761419</td>
</tr>
<tr>
<td>2025-05-23</td>
<td>Yutrepia</td>
<td>Liquidia Tech</td>
<td>NDA #213005</td>
<td>Treprostinil Sodium</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=213005</td>
</tr>
<tr>
<td>2025-05-28</td>
<td>Tryptyr</td>
<td>Alcon Labs Inc</td>
<td>NDA  #217370</td>
<td>Acoltremon</td>
<td>To treat the signs and symptoms of dry eye diseaseDrug Trials Snapshot</td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217370</td>
</tr>
<tr>
<td>2025-05-28</td>
<td>Khindivi</td>
<td>ETON</td>
<td>NDA #218980</td>
<td>Hydrocortisone</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218980</td>
</tr>
<tr>
<td>2025-05-30</td>
<td>Phenylephrine Hydrochloride IN 0.9% Sodium Chloride</td>
<td>Dr Reddys Labs SA</td>
<td>NDA  #216830</td>
<td>Phenylephrine Hydrochloride</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=216830</td>
</tr>
<tr>
<td>2025-04-02</td>
<td>Libervant</td>
<td>Aquestive</td>
<td>NDA #218623</td>
<td>Diazepam</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218623</td>
</tr>
<tr>
<td>2025-04-02</td>
<td>Vanrafia</td>
<td>Novartis</td>
<td>NDA #219208</td>
<td>Atrasentan Hydrochloride</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219208</td>
</tr>
<tr>
<td>2025-04-03</td>
<td>Piperacillin AND Tazobactam AND Sodium Chloride IN Duplex Container</td>
<td>B Braun Medical</td>
<td>NDA #206056</td>
<td>Piperacillin Sodium; Tazobactam Sodium</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=206056</td>
</tr>
<tr>
<td>2025-04-09</td>
<td>Trabectedin</td>
<td>Ever Valinject</td>
<td>NDA #219617</td>
<td>Trabectedin</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219617</td>
</tr>
<tr>
<td>2025-04-09</td>
<td>Jobevne</td>
<td>Biocon Biologics Inc</td>
<td>BLA #761175</td>
<td>Bevacizumab-NWGD</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761175</td>
</tr>
<tr>
<td>2025-04-10</td>
<td>Lopressor</td>
<td>Rubicon Research</td>
<td>NDA #219373</td>
<td>Metoprolol Tartrate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219373</td>
</tr>
<tr>
<td>2025-04-10</td>
<td>Livmarli</td>
<td>Mirum</td>
<td>NDA #219485</td>
<td>Maralixibat Chloride</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219485</td>
</tr>
<tr>
<td>2025-04-15</td>
<td>Mezofy</td>
<td>CMG Pharm Co Ltd</td>
<td>NDA #211448</td>
<td>Aripiprazole</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211448</td>
</tr>
<tr>
<td>2025-04-17</td>
<td>Eliquis</td>
<td>Bristol</td>
<td>NDA #220073</td>
<td>Apixaban</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220073</td>
</tr>
<tr>
<td>2025-04-17</td>
<td>Eliquis Sprinkle</td>
<td>Bristol</td>
<td>NDA #220073</td>
<td>Apixaban</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220073</td>
</tr>
<tr>
<td>2025-04-21</td>
<td>Carbon Dioxide, USP</td>
<td>Mitchell Wedling Supply</td>
<td>NDA #220461</td>
<td>Carbon Dioxide</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220461</td>
</tr>
<tr>
<td>2025-04-22</td>
<td>Qamzova</td>
<td>Nanjing Delova</td>
<td>NDA #217593</td>
<td>Meloxicam</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217593</td>
</tr>
<tr>
<td>2025-04-23</td>
<td>Penpulimab-KCQX</td>
<td>Akeso Biopharma</td>
<td>BLA #761258</td>
<td>Penpulimab-KCQX</td>
<td>In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapyDrug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761258</td>
</tr>
<tr>
<td>2025-04-29</td>
<td>Imaavy</td>
<td>Janssen Biotech</td>
<td>BLA #761430</td>
<td>Nipocalimab-AAHU</td>
<td>To treat generalized myasthenia gravisDrug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761430</td>
</tr>
<tr>
<td>2025-04-30</td>
<td>Atzumi</td>
<td>Satsuma Pharms</td>
<td>NDA #217901</td>
<td>Dihydroergotamine Mesylate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217901</td>
</tr>
<tr>
<td>2025-03-03</td>
<td>Tevimbra</td>
<td>Beigene</td>
<td>BLA #761380</td>
<td>Islelizumab-jsgr</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761380</td>
</tr>
<tr>
<td>2025-03-07</td>
<td>Omlyclo</td>
<td>Celltrion Inc</td>
<td>BLA #761399</td>
<td>Omalizumab-IGEC</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761399</td>
</tr>
<tr>
<td>2025-03-13</td>
<td>Epinephrine</td>
<td>Fresenius Kabi USA</td>
<td>NDA #215425</td>
<td>Epinephrine</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=215425</td>
</tr>
<tr>
<td>2025-03-13</td>
<td>Arbli</td>
<td>Scienture</td>
<td>NDA #218772</td>
<td>Losartan Potassium</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218772</td>
</tr>
<tr>
<td>2025-03-14</td>
<td>Tyenne</td>
<td>Fresenius Kabi USA</td>
<td>BLA #761449</td>
<td>Tocilizumab-AAZG</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761449</td>
</tr>
<tr>
<td>2025-03-17</td>
<td>Hemiclor</td>
<td>PRM Pharma</td>
<td>NDA #218647</td>
<td>Chlorthalidone</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218647</td>
</tr>
<tr>
<td>2025-03-20</td>
<td>Gozellix</td>
<td>Telix Innovations</td>
<td>NDA #219592</td>
<td>Gallium Ga-68 Gozetotide</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219592</td>
</tr>
<tr>
<td>2025-03-25</td>
<td>Blujepa</td>
<td>Glaxosmithkline</td>
<td>NDA #218230</td>
<td>Gepotidacin Mesylate</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218230</td>
</tr>
<tr>
<td>2025-03-25</td>
<td>Bomyntra</td>
<td>Fresenius Kabi USA LLC</td>
<td>BLA #761398</td>
<td>Denosumab-bnht</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761398</td>
</tr>
<tr>
<td>2025-03-25</td>
<td>Conexxence</td>
<td>Fresenius Kabi USA LLC</td>
<td>BLA #761398</td>
<td>Denosumab-bnht</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761398</td>
</tr>
<tr>
<td>2025-03-25</td>
<td>Denosumab-bnht</td>
<td>Fresenius Kabi USA LLC</td>
<td>BLA #761398</td>
<td>Denosumab-bnht</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761398</td>
</tr>
<tr>
<td>2025-03-26</td>
<td>Vykat XR</td>
<td>Soleno Therap</td>
<td>NDA #216665</td>
<td>Diazoxide Choline</td>
<td></td>
<td>Type 2 - New Active Ingredient</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=216665</td>
</tr>
<tr>
<td>2025-03-28</td>
<td>Qfitlia</td>
<td>Genzyme Corp</td>
<td>NDA   #219019</td>
<td>Fitusiran Sodium</td>
<td></td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219019</td>
</tr>
<tr>
<td>2025-02-02</td>
<td>Carbon Dioxide, USP</td>
<td>Welders Supply Company of Louisville Inc</td>
<td>NDA #220266</td>
<td>Carbon Dioxide</td>
<td></td>
<td>Medical Gas</td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=220266</td>
</tr>
<tr>
<td>2025-02-03</td>
<td>Onapgo</td>
<td>MDD US</td>
<td>NDA #214056</td>
<td>Apomorphine Hydrochloride</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=214056</td>
</tr>
<tr>
<td>2025-02-07</td>
<td>Emblaveo</td>
<td>Abbvie</td>
<td>NDA #217906</td>
<td>Avibactam Sodium; Aztreonam</td>
<td></td>
<td>Type 4 - New Combination</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=217906</td>
</tr>
<tr>
<td>2025-02-11</td>
<td>Evrysdi</td>
<td>Genentech Inc</td>
<td>NDA #219285</td>
<td>Risdiplam</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219285</td>
</tr>
<tr>
<td>2025-02-11</td>
<td>Gomekli</td>
<td>Springworks</td>
<td>NDA #219379</td>
<td>Mirdametinib</td>
<td>To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resectionÂ Drug Trials Snapshot</td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219379</td>
</tr>
<tr>
<td>2025-02-11</td>
<td>Gomekli</td>
<td>Springworks</td>
<td>NDA #219389</td>
<td>Mirdametinib</td>
<td>To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resectionÂ Drug Trials Snapshot</td>
<td>Type 3 - New Dosage Form</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219389</td>
</tr>
<tr>
<td>2025-02-13</td>
<td>Denosumab-dssb</td>
<td>Samsung Bioepis Co Ltd</td>
<td>BLA #761392</td>
<td>Denosumab-dssb</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761392</td>
</tr>
<tr>
<td>2025-02-13</td>
<td>Ospomyv</td>
<td>Samsung Bioepis Co Ltd</td>
<td>BLA #761392</td>
<td>Denosumab-dssb</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761392</td>
</tr>
<tr>
<td>2025-02-13</td>
<td>Xbryk</td>
<td>Samsung Bioepis Co Ltd</td>
<td>BLA #761392</td>
<td>Denosumab-dssb</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761392</td>
</tr>
<tr>
<td>2025-02-14</td>
<td>Romvimza</td>
<td>Deciphera Pharms</td>
<td>NDA #219304</td>
<td>Vimseltinib</td>
<td>To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidityDrug Trials Snapshot</td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219304</td>
</tr>
<tr>
<td>2025-02-14</td>
<td>Merilog</td>
<td>Sanofi-Aventis US LLC</td>
<td>BLA   #761325</td>
<td>Insulin Aspart-szjj</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761325</td>
</tr>
<tr>
<td>2025-02-14</td>
<td>Merilog Solostar</td>
<td>Sanofi-Aventis US LLC</td>
<td>BLA #761325</td>
<td>Insulin Aspart-szjj</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761325</td>
</tr>
<tr>
<td>2025-02-19</td>
<td>Nilotinib D-Tartrate</td>
<td>Cipla</td>
<td>NDA #218922</td>
<td>Nilotinib D-tartrate</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218922</td>
</tr>
<tr>
<td>2025-02-21</td>
<td>Diltiazem Hydrochloride in 0.72% Sodium Chloride</td>
<td>HQ SPCLT Pharma</td>
<td>NDA #218038</td>
<td>Diltiazem Hydrochloride</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218038</td>
</tr>
<tr>
<td>2025-02-21</td>
<td>Ctexli</td>
<td>Mirum</td>
<td>NDA #219488</td>
<td>Chenodiol</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219488</td>
</tr>
<tr>
<td>2025-02-24</td>
<td>Miudella</td>
<td>Sebela Womens HLTH</td>
<td>NDA   #218201</td>
<td>Copper</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218201</td>
</tr>
<tr>
<td>2025-02-28</td>
<td>Epinephrine Bitartrate in 0.9% Sodium Chloride</td>
<td>Baxter Hlthcare Corp</td>
<td>NDA #218475</td>
<td>Epinephrine Bitartrate</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=218475</td>
</tr>
<tr>
<td>2025-02-28</td>
<td>Osenvelt</td>
<td>Celltrion Inc</td>
<td>BLA #761404</td>
<td>Denosumab-bmwo</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761404</td>
</tr>
<tr>
<td>2025-02-28</td>
<td>Stoboclo</td>
<td>Celltrion Inc</td>
<td>BLA #761404</td>
<td>Denosumab-bmwo</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761404</td>
</tr>
<tr>
<td>2025-01-16</td>
<td>Brynovin</td>
<td>Azurity</td>
<td>NDA #219122</td>
<td>Sitagliptin Hydrochloride</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219122</td>
</tr>
<tr>
<td>2025-01-17</td>
<td>Myinfla</td>
<td>Columbia Therapeutics Inc</td>
<td>NDA #216469</td>
<td>Colchicine</td>
<td></td>
<td>Type 5 - New Formulation or New Manufacturer</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=216469</td>
</tr>
<tr>
<td>2025-01-17</td>
<td>Datroway</td>
<td>Daiichi Sankyo Inc</td>
<td>BLA #761394</td>
<td>Datopotamab Deruxtecan-dlnk</td>
<td>To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic diseaseDrug Trials Snapshot</td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761394</td>
</tr>
<tr>
<td>2025-01-21</td>
<td>Grafapex</td>
<td>Medexus</td>
<td>NDA #214759</td>
<td>Treosulfan</td>
<td>For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromeDrug Trials Snapshot</td>
<td>Type 1 - New Molecular Entity</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=214759</td>
</tr>
<tr>
<td>2025-01-24</td>
<td>Avtozma</td>
<td>Celltrion Inc</td>
<td>BLA #761420</td>
<td>Tocilizumab-anoh</td>
<td></td>
<td></td>
<td></td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761420</td>
</tr>
<tr>
<td>2025-01-28</td>
<td>Inzirqo</td>
<td>Novitium Pharma</td>
<td>NDA #219141</td>
<td>Hydrochlorothiazide</td>
<td></td>
<td>Type 3 - New Dosage Form</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219141</td>
</tr>
<tr>
<td>2025-01-30</td>
<td>Symbravo</td>
<td>Axsome</td>
<td>NDA #215431</td>
<td>Meloxicam; Rizatriptan Benzoate</td>
<td></td>
<td>Type 4 - New Combination</td>
<td>Standard</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=215431</td>
</tr>
<tr>
<td>2025-01-30</td>
<td>Journavx</td>
<td>Vertex Pharms Inc</td>
<td>NDA #219209</td>
<td>Suzetrigine</td>
<td>To treat moderate to severe acute painPress ReleaseÂ Drug Trials Snapshot</td>
<td>Type 1 - New Molecular Entity</td>
<td>Priority</td>
<td>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=219209</td>
</tr>
</tbody>
</table>
</div>
</main>
<script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
<script src="https://cdn.datatables.net/2.0.7/js/dataTables.min.js"></script>
<script src="https://cdn.datatables.net/buttons/3.0.2/js/dataTables.buttons.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
<script src="https://cdn.datatables.net/buttons/3.0.2/js/buttons.html5.min.js"></script>
<script src="https://cdn.datatables.net/buttons/3.0.2/js/buttons.print.min.js"></script>
<script>
    new DataTable('#tbl_main', {
      dom: 'Bfrtip',
      buttons: [
        { extend:'csv', className:'btn btn-default' },
        { extend:'excel', className:'btn btn-default' },
        { extend:'print', className:'btn btn-default' }
      ],
      pageLength: 25,
      responsive: true,
      autoWidth: false,
      columnDefs: [
        { targets: '_all', defaultContent: '' }
      ]
    });
  </script>
</body>
</html>
